Last reviewed · How we verify
GerEPO
GerEPO is an erythropoietin (EPO) analog that stimulates red blood cell production by binding to the erythropoietin receptor on bone marrow progenitor cells.
GerEPO is an erythropoietin (EPO) analog that stimulates red blood cell production by binding to the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy.
At a glance
| Generic name | GerEPO |
|---|---|
| Sponsor | Ministry of Health, Malaysia |
| Drug class | Erythropoietin receptor agonist |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
GerEPO functions as an erythropoiesis-stimulating agent (ESA) that mimics the action of endogenous erythropoietin, promoting the proliferation and differentiation of erythroid progenitor cells in the bone marrow. This leads to increased hemoglobin and red blood cell production, addressing anemia in patients with chronic kidney disease or other conditions associated with EPO deficiency.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
Common side effects
- Hypertension
- Thrombotic events
- Headache
- Injection site reactions
Key clinical trials
- Efficacy and Safety Study of GerEPO (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |